Who is sponsoring NCT06840470?

NCT06840470 is sponsored by University of Michigan.

What drugs are being tested in NCT06840470?

Interventions in NCT06840470: Imiquimod 5% Topical Cream.

What condition does NCT06840470 study?

NCT06840470 studies Sebaceous Hyperplasia.

Is NCT06840470 still recruiting?

NCT06840470 is currently recruiting now. Last updated 1 April 2025.

Last reviewed 2025-04-01 · How we verify

NCT06840470

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia

Recruiting now Phase 4 Last updated 1 April 2025

What this trial tests

Phase 4 trial testing Imiquimod 5% Topical Cream in Sebaceous Hyperplasia in 40 participants. Currently enrolling.

Timeline

11 March 2025

Primary endpoint
11 March 2027

11 September 2027

Quick facts

Lead sponsor	University of Michigan
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	11 March 2025
Primary completion	11 March 2027
Estimated completion	11 September 2027
Sites	1 location across United States

Drugs / interventions tested

Imiquimod 5% Topical Cream — full drug profile →

Conditions studied

Sebaceous Hyperplasia — all drugs for Sebaceous Hyperplasia →

Sponsor

University of Michigan

Who can join

18 and older, any sex, with Sebaceous Hyperplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is being completed to determine if 8 weeks of treatment with imiquimod can shrink sebaceous hyperplasia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Imiquimod 5% Topical Cream

Trials testing the same drug.

NCT04072900 — A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma · Phase 1 · unknown

Other University of Michigan trials

Trials by the same sponsor.

NCT07536919 — Integrating Care for Hypertension-Diabetes MULTImorbidity in Guatemala Through HEARTS Implementation · NA · not yet recruiting
NCT05509842 — Function-based Accelerated Stimulation Therapy (FAST-therapy) for Freezing of Gait (FOG) After Parkinson's Disease (PD) · NA · not yet recruiting
NCT06311188 — Exploring PTSD Symptoms, Barriers and Facilitators to Mindfulness · NA · not yet recruiting
NCT07471646 — Effects of Ramadan Fasting With Exercise on Cardiometabolic Health · NA · not yet recruiting
NCT06671925 — A Community Health Worker-Led Program for Chronic Pain and Loneliness in Older Adults · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06840470 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Michigan
Last refreshed: 1 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06840470.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing